Cellid Co., Ltd. Logo

Cellid Co., Ltd.

Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.

299660 | KO

Overview

Corporate Details

ISIN(s):
KR7299660001
LEI:
Country:
South Korea
Address:
서울시 관악구 관악로 1 서울대학교 142동 5층, 서울시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellid Co., Ltd. is a research and development-focused biotechnology company specializing in immunotherapeutic vaccines for cancer and infectious diseases. The company's core business is centered on its proprietary technology platforms. Its key offering, CeliVax, is an anti-cancer immunotherapeutic vaccine platform that utilizes a patient's own B cells and monocytes, designed to be applicable to any cancer with identified antigens. In addition, Cellid has developed an adenovirus vector-based platform for creating preventive vaccines against infectious diseases, notably used in the development of a COVID-19 vaccine. The company's pipeline is focused on leveraging these technologies to address significant unmet medical needs in oncology and virology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 8.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1015.8 KB
2025-08-12 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구)
Korean 7.0 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 28.4 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 27.6 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 26.2 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 27.6 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 26.2 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB

Automate Your Workflow. Get a real-time feed of all Cellid Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellid Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellid Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.